Two-step transcriptional amplification-lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer

Cancer Science

Volumn 97, Issue 8, 2006, Pages 787-798

  Hattori, Yoshiyuki ^a   Maitani, Yoshie ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ETOPOSIDE; GANCICLOVIR; HERPES SIMPLEX THYMIDINE KINASE; HYBRID PROTEIN; LUCIFERASE; MIDKINE; NANOPARTICLE; PLASMID VECTOR; PROSTATE SPECIFIC MEMBRANE ANTIGEN; THYMIDINE KINASE; TRANSCRIPTION FACTOR GAL4; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENZYME ACTIVITY; ENZYME ASSAY; GENE AMPLIFICATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN FUNCTION; SUICIDE GENE THERAPY; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, SURFACE; CELL LINE, TUMOR; CYTOKINES; ENHANCER ELEMENTS (GENETICS); GENE AMPLIFICATION; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LIPIDS; LUCIFERASES; MALE; MICE; NANOSTRUCTURES; PLASMIDS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RNA, MESSENGER; THYMIDINE KINASE; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33745620050     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00243.x     Document Type: Article

References (42)

1. El Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release 2004; 94: 1-14.
2. Dass CR, Burton MA. Lipoplexes and tumours. A review. J Pharm Pharmacol 1999; 51: 755-70.
3. Gao X, Porter AT, Grignon DJ, Pontes JE, Honn KV. Diagnostic and prognostic markers for human prostate cancer. Prostate 1997; 31: 264-81.
4. Suzuki S, Tadakuma T, Asano T, Hayakawa M. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations. Cancer Res 2001; 61: 1276-9.
5. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81-5.
6. Wright GL Jr, Grob BM, Haley C et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-34.
7. Uchida A, O'Keefe DS, Bacich DJ, Molloy PL, Heston WD. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: A potential alternative approach to androgen deprivation therapy. Urology 2001; 58: 132-9.
8. Kadomatsu K, Tomomura M, Muramatsu T. cDNA cloning and sequencing of a new gene intensely expressed in early differentiation stages of embryonal carcinoma cells and in mid-gestation period of mouse embryogenesis. Biochem Biophys Res Commun 1988; 151: 1312-18.
9. Sekiguchi K, Yokota C, Asashima M et al. Restricted expression of Xenopus midkine gene during early development. J Biochem (Tokyo) 1995; 118: 94-100.
10. Tsutsui J, Kadomatsu K, Matsubara S et al. A new family of heparin-binding growth/differentiation factors: Increased midkine expression in Wilms' tumor and other human carcinomas. Cancer Res 1993; 53: 1281-5.
11. Garver RI Jr, Radford DM, Donis-Keller H, Wick MR, Milner PG. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 1994; 74: 1584-90.
12. Konishi N, Nakamura M, Nakaoka S et al. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 1999; 57: 253-7.
13. Yoshida Y, Tomizawa M, Bahar R et al. A promoter region of midkine gene can activate transcription of an exogenous suicide gene in human pancreatic cancer. Anticancer Res 2002; 22: 117-20.
14. Yoshimura I, Suzuki S, Tadakuma T, Hayakawa M. Suicide gene therapy on LNCaP human prostate cancer cells. Int J Urol 2001; 8: S5-S8.
15. Segawa T, Takebayashi H, Kakehi Y, Yoshida O, Narumiya S, Kakizuka A. Prostate-specific amplification of expanded polyglutamine expression: A novel approach for cancer gene therapy. Cancer Res 1998; 58: 2282-7.
16. Iyer M, Wu L, Carey M, Wang Y, Smallwood A, Gambhir SS. Two-step transcriptional amplification as a method for imaging reporter gene expression using weak promoters. Proc Natl Acad Sci USA 2001; 98: 14595-600.
17. Ikegami S, Tadakuma T, Suzuki S, Yoshimura I, Asano T, Hayakawa M. Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition. Jpn J Cancer Res 2002; 93: 1154-63.
18. Yoshimura I, Ikegami S, Suzuki S, Tadakuma T, Hayakawa M. Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. J Urol 2002; 168: 2659-64.
19. Gschwend JE, Fair WR, Powell CT. Evaluation of the tetracycline-repressible transactivator system for inducible gene expression in human prostate cancer cell lines. Prostate 1997; 33: 166-76.
20. Block A, Milasinovic D, Mueller J, Schaefer P, Schaefer H, Greten H. Amplified Muc1-specific gene expression in colon cancer cells utilizing a binary system in adenoviral vectors. Anticancer Res 2002; 22: 3285-92.
21. Koch PE, Guo ZS, Kagawa S, Gu J, Roth JA, Fang B. Augmenting transgene expression from carcinoembryonic antigen (CEA) promoter via a GAL4 gene regulatory system. Mol Ther 2001; 3: 278-83.
22. Hattori Y, Maitani Y. Folate-linked nanoparticle-mediated suicide gene therapy in human prostate cancer with herpes simplex virus thymidine kinase and connexin 43. Cancer Gene Ther 2005; 12: 796-809.
23. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 1989; 77: 51-9.
24. Pang S, Dannull J, Kaboo R et al. Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. Cancer Res 1997; 57: 495-9.
25. Hattori Y, Kubo H, Higashiyama K, Maitani Y. Folate-linked nanoparticles formed with DNA complexes in sodium chloride solution enhance transfection efficiency. J Biomed Nanotechnol 2005; 1: 176-84.
26. Rein DT, Breidenbach M, Nettelbeck DM et al. Evaluation of tissue-specific promoters in carcinomas of the cervix uteri. J Gene Med 2004; 6: 1281-9.
27. Good D, Schwarzenberger P, Eastham JA et al. Cloning and characterization of the prostate-specific membrane antigen promoter. J Cell Biochem 1999; 74: 395-405.
28. Young CY, Montgomery BT, Andrews PE, Qui SD, Bilhartz DL, Tindall DJ. Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 1991; 51: 3748-52.
29. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WD. Expression of the prostate-specific membrane antigen. Cancer Res 1994; 54: 1807-11.
30. Noss KR, Wolfe SA, Grimes SR. Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. Gene 2002; 285: 247-56.
31. Watt F, Martorana A, Brookes DE et al. A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. Genomics 2001; 73: 243-54.
32. Zeng H, Wu Q, Li H et al. Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer. J Androl 2005; 26: 215-21.
33. Miyauchi M, Shimada H, Kadomatsu K et al. Frequent expression of midkine gene in esophageal cancer suggests a potential usage of its promoter for suicide gene therapy. Jpn J Cancer Res 1999; 90: 469-75.
34. Matsubara S, Take M, Pedraza C, Muramatsu T. Mapping and characterization of a retinoic acid-responsive enhancer of midkine, a novel heparin-binding growth/differentiation factor with neurotrophic activity. J Biochem (Tokyo) 1994; 115: 1088-96.
35. Pang S. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene. Cancer Gene Ther 2000; 7: 991-6.
36. Ellis WJ, Vessella RL, Buhler KR et al. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23. Clin Cancer Res 1996; 2: 1039-48.
37. O'Keefe DS, Uchida A, Bacich DJ et al. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate 2000; 45: 149-57.
38. Adachi Y, Matsubara S, Muramatsu T, Curiel DT, Reynolds PN. Midkine promoter-based adenoviral suicide gene therapy to midkine-positive pediatric tumor. J Pediatr Surg 2002; 37: 588-92.
39. Laidler P, Dulinska J, Lekka M, Lekki J. Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. Arch Biochem Biophys 2005; 435: 1-14.
40. Zhang L, Adams JY, Billick E et al. Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer. Mol Ther 2002; 5: 223-32.
41. Sato M, Johnson M, Zhang L et al. Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy. Mol Ther 2003; 8: 726-37.
42. Iyer M, Salazar FB, Lewis X et al. Noninvasive imaging of enhanced prostate-specific gene expression using a two-step transcriptional amplification-based lentivirus vector. Mol Ther 2004; 10: 545-52.